Get the Stockscreener App
10.31
0.77%
-0.08
After Hours:
10.31
Elanco Animal Health Inc stock is traded at $10.31, with a volume of 3.39M.
It is down -0.77% in the last 24 hours and down -11.58% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$10.39
Open:
$10.35
24h Volume:
3.39M
Relative Volume:
0.75
Market Cap:
$5.10B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
25.77
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
-4.80%
1M Performance:
-11.58%
6M Performance:
-28.75%
1Y Performance:
-35.20%
1-Day Range:
$10.14
$10.44
1-Week Range:
$10.03
$11.19
52-Week Range:
$10.03
$18.80
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
10.31 | 5.10B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
160.06 | 71.67B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.44B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.36 | 13.97B | 612.78M | -86.37M | -62.91M | -0.87 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
AI-In Animal Health Market Is Booming So Rapidly | Elanco, Covetrus, Vetoquinol - openPR
Are Options Traders Betting on a Big Move in Elanco Animal Health (ELAN) Stock? - Yahoo Finance
Elanco’s SWOT analysis: animal health stock poised for growth amid challenges - Investing.com India
Director Makes Bold Move with Major Stock Purchase in Elanco Animal Health - TipRanks
Why Elanco Animal Health Incorporated (ELAN) Went Down on Tuesday - Yahoo Finance
Elanco Animal Health director Lawrence Kurzius buys $211,000 in stock - Investing.com
Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4) - Quantisnow
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Proficio Capital Partners LLC Makes New $405,000 Investment in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Elanco Animal Health Reports Fourth Quarter and Full Year 2024 R - GuruFocus.com
Elanco Enters Agreement with Medgene to Commercialize Highly Pat - GuruFocus.com
Bank of New York Mellon Corp Has $24.31 Million Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation - Markets Insider
Piper Sandler Cuts Elanco Animal Health (NYSE:ELAN) Price Target to $12.00 - Defense World
Principal Financial Group Inc. Has $309,000 Stake in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Director’s Bold Move: Major Investment in Elanco Animal Health - TipRanks
Elanco Animal Health (NYSE:ELAN) Price Target Lowered to $12.00 at Piper Sandler - MarketBeat
Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle - Hoard's Dairyman
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out - Markets Insider
Tesla To $370? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Elanco teams with Medgene to commercialize pathogenic avian influenza vaccine - dairyfoods.com
Shareholder Alert: Johnson Fistel, LLP Investigates Elanco Animal Health, Fox Factory Holding, Fidelity National Information, and Bank of America —Long-Term Investors are Encouraged to Contact the Firm - GlobeNewswire
Officer De Brabander Ellen was granted 50,575 shares, increasing direct ownership by 30% to 221,740 units (SEC Form 4) - Quantisnow
Officer Bettington Timothy J was granted 30,947 shares, increasing direct ownership by 30% to 133,820 units (SEC Form 4) - Quantisnow
Europe Dog Dewormers Market Report 2025-2030: Zoetis, - GlobeNewswire
Europe Dog Dewormers Market Report 2025-2030: Zoetis, Boehringer Ingelheim, Merck & Co., Dechra Pharmaceuticals, and Elanco Animal Health Dominate Shares - Yahoo Finance
Linscomb Wealth Inc. Has $287,000 Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Receives $15.83 Consensus Price Target from Analysts - MarketBeat
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL
EVP, MANUFACTURING AND QUALITY Mcardle Grace covered exercise/tax liability with 3,430 shares, decreasing direct ownership by 6% to 52,211 units (SEC Form 4) - Quantisnow
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out - Markets Insider
Elanco Animal Health: Undervalued Growth Potential with Strong Product Performance and Debt Reduction - TipRanks
Dogs Vaccines Market Detailed In New Research Report 2025 | - openPR
Veterinary Pharmacovigilance Market Is Booming So Rapidly | Elanco, Norbrook, Bimeda - openPR
Illinois Municipal Retirement Fund Has $4.56 Million Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Why Big Pharma wants you to eat more meat - Vox.com
New York State Common Retirement Fund Decreases Position in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Phocas Financial Corp. - MarketBeat
Truist Financial Corp Purchases 120,596 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Barclays Lowers Elanco Animal Health (NYSE:ELAN) Price Target to $19.00 - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Elanco Animal Health Incorporated (ELAN) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Elanco Animal Health (NYSE:ELAN) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Skylands Capital LLC - MarketBeat
Decoding Elanco Animal Health Inc (ELAN): A Strategic SWOT Insig - GuruFocus.com
Elanco Animal Health Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – ELAN - ACCESS Newswire
ELANCO FRAUD ALERT: Elanco (NYSE:ELAN) Shareholders that Suffered Losses are Alerted to Contact BFA Law about Investigation into the Company for Securities Fraud - ACCESS Newswire
Elanco’s Earnings Call: Growth Amid Challenges - TipRanks
Elanco Animal Health (NYSE:ELAN) Price Target Cut to $17.00 by Analysts at UBS Group - MarketBeat
Is Elanco Animal Health Incorporated (ELAN) the Best Low Price Pharma Stock to Invest In Right Now? - Yahoo Finance
Elanco launches new line of dog supplements - Pet Food Processing
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):